GLP-1 Receptor Agonists Associated with Reduced Mortality in Elderly Cancer Patients with T2D
A recent study shows that GLP-1 receptor agonists are associated with lower mortality rates in elderly cancer patients with type 2 diabetes, offering promising survival benefits in this vulnerable population.
Recent research indicates that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is linked to a decrease in all-cause mortality among older adults suffering from both cancer and type 2 diabetes (T2D). Published online on July 18, 2025, in JAMA Network Open, the study highlights the potential survival benefits of this medication class compared to other antidiabetic drugs.
The study, led by Dr. Rotana M. Radwan from the University of Florida, analyzed Medicare data from 2013 to 2020, focusing on patients aged 66 and older diagnosed with one of nine common cancers, including breast, lung, colorectal, pancreatic, and others, alongside T2D. Using retrospective cohort methods and propensity score matching, researchers compared outcomes between patients on GLP-1 RAs, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP4i).
Findings revealed that, while there was no significant difference in mortality risk between GLP-1 RAs and SGLT2i users, patients on GLP-1 RAs had a significantly lower risk of death compared to those on DPP4i, with a hazard ratio of 0.60. The survival advantage persisted across various subgroups, including different ages, sexes, races, and cancer types such as colorectal, lung, and breast cancers.
The authors suggest that the systemic effects of GLP-1 RAs might contribute to these observed survival benefits, although they caution that causality cannot be definitively established. Notably, some authors disclosed ties to the biopharmaceutical industry, emphasizing the need for further research.
This study adds important evidence to the potential clinical benefits of GLP-1 receptor agonists in managing complex cases involving cancer and diabetes in the elderly, potentially influencing future therapeutic strategies.
For more details, the full study can be accessed via JAMA Network Open, DOI: 10.1001/jamanetworkopen.2025.21887.
(Source: https://medicalxpress.com/news/2025-07-glp-receptor-agonist-linked-mortality.html)
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Brain Power and Cognitive Skills in Hockey: Position-Specific Brain Processing Revealed by Study
Recent research reveals that hockey players' cognitive processing speeds vary by position, and targeted brain training can enhance their performance and safety on the ice. Using portable neurotechnology, athletes can now measure and improve neural responses for better reaction times and decision-making.
Research Shows No Advantage of Dual Antiplatelet Therapy Over Aspirin Alone After Heart Bypass Surgery
A new study reveals that dual antiplatelet therapy offers no additional benefit over aspirin alone after coronary artery bypass surgery, but increases bleeding risks, leading to potential changes in treatment guidelines.
Sleep Disorders as Potential Early Signs of Neurodegenerative Diseases
Emerging research links sleep disorders like REM Sleep Behavior Disorder (RBD) to the early development of neurodegenerative diseases such as Parkinson's and Lewy body dementia, offering promising avenues for early diagnosis and intervention.
Breakthrough Clinical Trial Shows Therapeutic Plasma Exchange Can Rejuvenate Biological Age
A groundbreaking clinical trial reveals that therapeutic plasma exchange combined with IVIG can reduce biological age by over two years, highlighting new potential for aging interventions and longevity research.